Advertisement
Canada markets open in 9 hours 23 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7303
    +0.0005 (+0.07%)
     
  • CRUDE OIL

    82.87
    +0.06 (+0.07%)
     
  • Bitcoin CAD

    88,041.06
    -3,229.14 (-3.54%)
     
  • CMC Crypto 200

    1,391.16
    -32.94 (-2.31%)
     
  • GOLD FUTURES

    2,325.30
    -13.10 (-0.56%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,460.25
    -204.25 (-1.16%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    37,708.41
    -751.67 (-1.95%)
     
  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Bluebird Bio Misses Analysts’ Estimates in Q2 2018

Bluebird Bio Misses Analysts’ Estimates in Q2 2018

Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.